NVCT — Nuvectis Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875558 ·
Last close
$10.10
Market Cap
$267.91M
52W High
$13.34
52W Low
$7.17
ADV30
95,756
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,260,000 | -6,050,000 | 25,398,000 | 25,130,000 | 11,178,000 |
| Dec 2025 | 0 | — | -7,617,000 | -7,314,000 | 31,709,000 | 31,634,000 | 13,296,000 |
| Sep 2025 | 0 | — | -7,794,000 | -7,462,000 | 35,587,000 | 35,442,000 | 11,577,000 |
| Jun 2025 | 0 | — | -6,595,000 | -6,334,000 | 27,007,000 | 26,793,000 | 10,135,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,009,000
Investing CF
$0
Financing CF
$29,110,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-99,687,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,574,000
Pretax Income TTM
$-26,442,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,574,000 | -26,442,000 | 31,709,000 | 13,296,000 | — | -16,009,000 |
| Dec 2024 | 0 | -19,847,000 | -19,000,000 | 18,607,000 | 8,894,000 | — | -12,247,000 |
| Dec 2023 | 0 | -22,897,000 | -22,260,000 | 19,185,000 | 6,984,000 | — | -15,954,000 |
| Dec 2022 | 0 | -19,234,000 | -19,085,000 | 20,405,000 | 6,186,000 | — | -13,559,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | $265.51M | $4.09 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $264.43M | $1.73 | — |
| TRDA | Entrada Therapeutics, Inc. | $260.10M | $6.70 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $259.71M | $1.93 | — |
| AKBA | Akebia Therapeutics, Inc. | $278.99M | $1.04 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
2026-05-25 13:55 · Yahoo
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-14 11:30 · Yahoo
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
2026-05-07 13:55 · Yahoo
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-05 11:30 · Yahoo
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma
2026-05-04 10:36 · Yahoo
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
2026-03-31 12:00 · Yahoo
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
2026-03-24 12:27 · Yahoo
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
2026-02-11 12:30 · Yahoo
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
2025-12-17 12:00 · Yahoo
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
2025-12-05 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.